TNF and irritable bowel syndrome: Several novel therapeutic targets have been proven helpful in treating IBD (4), whereas tumor necrosis factor (TNF) antagonists remain the cornerstone of treatment for moderately to highly active IBD, with approximately 70% primary response rates in placebo-controlled trials (5, 6).